Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Rocapuldencel T (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics
- 03 Jan 2018 Status changed from withdrawn prior to enrolment to discontinued
- 15 Sep 2017 Planned End Date changed from 18 Jul 2019 to 1 Sep 2017.
- 15 Sep 2017 Planned primary completion date changed from 14 Jul 2018 to 1 Sep 2017.